Skip to content

Study · Randomized controlled trial · n = 96 · 2010

4 results

Efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke.

Bajenaru O, Tiu C, Moessler H, Antochi F, Muresanu D, Popescu BO, Novak P

Journal of medicine and life1 Apr 2010Cited by 9 (Europe PMC)

PMID20968198 (opens in a new tab)PMCIDPMC3019043 (opens in a new tab)PepBankPUB-20968198
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

UnlabelledThe purpose of the study was to investigate the efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke. The primary objective of this trial was to assess the clinical efficacy and safety of a 10-days course of therapy with a daily administration of Cerebrolysin (50 mL i.v. per day). The trial had to demonstrate that Cerebrolysin treatment is safe in hemorrhagic stroke.MethodsThe study was performed as a prospective, randomized, double blind, placebo-controlled, parallel group study with 2 treatment groups. Efficacy measures were the Unified Neurological Stroke Scale, Barthel Index, and Syndrome Short Test. The duration of the trial was of 21 days for each patient. Out of 100 randomized patients, a total of 96 (96%) completed the study.ResultsOverall, no statistically significant group effects were observed based on single average comparisons at the individual visits. It could be shown that the treatment of hemorrhagic stroke with Cerebrolysin is safe and well tolerated.ConclusionIn the changes of UNSS, BI and SST from baseline to day 21, the group differences are not statistically significant; however, the use of Cerebrolysin in hemorrhagic stroke is safe and well tolerated and studies with a larger sample size may provide statistical evidence of Cerebrolysin's efficacy in patients with hemorrhagic stroke.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In hemorrhagic stroke patients, Cerebrolysin and placebo did not differ significantly in Unified Neurological Stroke Scale at individual visits or baseline-to-day-21 changes.

    In plain wordsIn hemorrhagic stroke patients, Cerebrolysin and placebo did not differ significantly in UNSS at visits or baseline-to-day-21 changes.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeUnified Neurological Stroke Scale
    Study

    n = 96

    Comparator
    Placebo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    50 mL per day · intravenous · 10 daysAs given in this study (human).

    Source sentences

    Summary
    In the changes of UNSS, BI and SST from baseline to day 21, the group differences are not statistically significant
    Summary
    Overall, no statistically significant group effects were observed based on single average comparisons at the individual visits.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In hemorrhagic stroke patients, Cerebrolysin and placebo did not differ significantly in Barthel Index at individual visits or baseline-to-day-21 changes.

    In plain wordsIn hemorrhagic stroke patients, Cerebrolysin and placebo did not differ significantly in BI at visits or baseline-to-day-21 changes.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeBarthel Index
    Study

    n = 96

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    50 mL per day · intravenous · 10 daysAs given in this study (human).

    Source sentences

    Summary
    In the changes of UNSS, BI and SST from baseline to day 21, the group differences are not statistically significant
    Summary
    Overall, no statistically significant group effects were observed based on single average comparisons at the individual visits.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In hemorrhagic stroke patients, Cerebrolysin and placebo did not differ significantly in Syndrome Short Test at individual visits or baseline-to-day-21 changes.

    In plain wordsIn hemorrhagic stroke patients, Cerebrolysin and placebo did not differ significantly in SST at visits or baseline-to-day-21 changes.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeSyndrome Short Test
    Study

    n = 96

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    50 mL per day · intravenous · 10 daysAs given in this study (human).

    Source sentences

    Summary
    In the changes of UNSS, BI and SST from baseline to day 21, the group differences are not statistically significant
    Summary
    Overall, no statistically significant group effects were observed based on single average comparisons at the individual visits.
  4. 04HumanRandomized controlled trialSafety outcome

    In hemorrhagic stroke patients, Cerebrolysin was reported as safe and well tolerated without specific adverse-event data.

    In plain wordsIn hemorrhagic stroke patients, Cerebrolysin was reported as safe and well tolerated without specific adverse-event data.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableOverall safety and tolerability
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    50 mL per day · intravenous · 10 daysAs given in this study (human).

    Source sentences

    Summary
    It could be shown that the treatment of hemorrhagic stroke with Cerebrolysin is safe and well tolerated.
    1 context sentence
    Summary · context
    The study was performed as a prospective, randomized, double blind, placebo-controlled, parallel group study with 2 treatment groups.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.